Recent Advances in ECG Analysis for ProArrhythmia Risk Assessment: The Need to Read Between the Line

In the last 5 years, FDA has actively characterized innovative ECG analysis methods for proarrhythmia assessments in clinical trials. ECG is a cornerstone of cardiac safety monitoring in toxicology and safety pharmacology with similarities between clinical and non-clinical evaluations.

A presentation was given by CitoxLab North America during SOT Annual Meeting & ToxExpo 2019, in Baltimore:

Recent Advances in ECG Analysis for ProArrhythmia Risk Assessment: The Need to Read Between the Line

 

Other posts you may like

SOT 59th Annual Meeting and ToxExpo

Wednesday March 18th, 2020 Anaheim, CA - USA

Happy Holidays from all of us at emka TECHNOLOGIES

Please take note that our offices will be closed during holidays. Consult the dates here.

Pharmacology 2019

December 15-17, 201 Edinburgh, UK Booth #14

Molecular Biology Society of Japan

December 03-06, 2019 Fukuoka, Japan